Q1 2025 Earnings Call Transcript May 7, 2025 EyePoint Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.65 EPS, expectations were $-0.65. Operator: Good morning. My ...

Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) ...

In advanced dry age-related macular degeneration (AMD ... significant protection of photoreceptors as measured by optical coherence tomography (OCT) and supported by slowing of loss of retinal ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Topcon Healthcare acquired RetInSight, an Austria-based company that develops AI-driven software for eye care professionals, ...

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

Research and development expenses for the first quarter of 2025 were $42.9 million versus $20.7 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...